Only a part of prostate cancer (PCa) patients has aggressive malignancy requiring adjuvant treatment after radical prostatectomy (RP). Biomarkers capable to predict biochemical PCa recurrence (BCR) after RP would significantly improve preoperative risk stratification and treatment decisions. MicroRNA (miRNA) deregulation has recently emerged as an important phenomenon in tumor development and progression, however, the mechanisms remain largely unstudied. In the present study, based on microarray profiling of DNA methylation in 9 pairs of PCa and noncancerous prostate tissues (NPT), host genes of miR-155-5p, miR-152-3p, miR-137, miR-31-5p, and miR-642a, -b were analyzed for promoter methylation in 129 PCa, 35 NPT, and 17 benign prostatic hyperplasia samples (BPH) and compared to the expression of mature miRNAs and their selected targets (DNMT1, KDM1A, and KDM5B). The Cancer Genome Atlas dataset was utilized for validation. Methylation of mir-155, mir-152, and mir-137 host genes was PCa-specific, and downregulation of miR-155-5p significantly correlated with promoter methylation. Higher KDM5B expression was observed in samples with methylated mir-155 or mir-137 promoters, whereas upregulation of KDM1A and DNMT1 was associated with mir-155 and mir-152 methylation status, respectively. Promoter methylation of mir-155, mir-152, and mir-31 was predictive of BCR-free survival in various Cox models and increased the prognostic value of clinicopathologic factors. In conclusion, methylated mir-155, mir-152, mir-137, and mir-31 host genes are promising diagnostic and/or prognostic biomarkers of PCa. Methylation status of particular miRNA host genes as independent variables or in combinations might assist physicians in identifying poor prognosis PCa patients preoperatively.
Introduction
Prostate cancer (PCa) is one of the most commonly diagnosed malignancies worldwide and the fifth leading cause of cancerrelated death among men (1) . During the last decade, the widespread prostate-specific antigen (PSA) testing has significantly improved early detection of PCa and increased the prevalence of localized tumors that would have otherwise remained undetected, altogether resulting in >80% of new cases being organconfined at the time of diagnosis (2) . However, biomarkers that could accurately determine PCa aggressiveness are still lacking. Previous studies have reported a broad range of biochemical disease recurrence (BCR) rate after radical prostatectomy (RP), varying from 10% to 40%, with nearly half of these patients receiving androgen deprivation therapy in combination with salvage radiotherapy (3, 4) .
Currently used prognostic indicators, like pathological tumor stage, Gleason score and pretreatment PSA level, are unable to predict accurately cancer progression at the time of diagnosis, which has resulted in PCa overtreatment in the PSA era (5) . At present, the increasing PSA level after RP is the main marker for PCa prognosis, however, PSA increase indicates disease relapse only after its occurrence. Therefore, biomarkers that can predict PCa progression at the time of diagnosis are urgently needed in clinical practice. The capability to predict PCa relapse early would expectantly have significant outcomes enabling the physicians to select the most appropriate treatment modality or to administer adjuvant therapy at the earliest time.
Epigenetic alterations have been widely recognized as an early event in oncogenesis and might be associated with disease progression. Recently, epigenetic silencing of microRNAs (miRNAs) has emerged as an important mechanism of oncogenesis (6) . MiRNAs are approximately 20-22 nt single-stranded non-coding RNAs that negatively regulate target gene expression by binding mostly to 3' untranslated region (3'-UTR) of target mRNAs, which causes mRNA cleavage or translational repression (7) . In mammalian genomes, some of the miRNA genes are located among known annotated genes, whereas others are hosted inside protein-coding or non-coding transcribed genes. Some of these miRNAs, especially intronic, are coordinately expressed with their hosts (8) (9) (10) .
A particular miRNA can interact with multiple mRNAs and, therefore, it has a potential to regulate a large network of targets. At present, 2588 mature human miRNAs (1881 precursors) have been described (miRBase release 21; http://www.mirbase.org; date last accessed November 15, 2016) , while tremendous efforts to identify their numerous targets are ongoing. Depending on the targets being regulated, miRNAs act as tumor suppressors (miR-137, miR-152, miR-31), oncogenic miRNAs (miR-21, miR-9), or have mixed roles (miR-125b, miR-155) (6) . Epigenetic downregulation of a specific miRNA might result in the increased expression of multiple target genes or reactivation of previously silenced sequences. Such upregulation of genes coding epigenetic factors, i.e. epigenetic modulators and other proteins that are critical for enzymatic complexes, leads to global changes in the epigenome and, consequently, tumor development (11, 12) . Somatic mutations in PCa are less common that in other solid tumors (13) and, thus, do not explain the frequent deregulation of epigenetic factors. Therefore, the significance of various epigenetic mechanisms accounting for aberrant expression of these epigenetic factors is being investigated.
In this study, we aimed to analyze the diagnostic and prognostic potential of the promoter methylation status of the miRNA host genes in PCa. A two-step approach was used in the present study utilizing The Cancer Genome Atlas (TCGA) data to validate our findings (13) . Initially, 5 genes coding mir-155, mir-152, mir-137, mir-31, and mir-642a, -b were chosen from DNA methylation microarray data for the promoter methylation analysis in PCa and control samples. Methylated promoter status was associated with downregulation of the respective miRNAs. Furthermore, the expression levels of several epigenetic modulator genes (DNMT1, KDM1A, and KDM5B) as direct targets of miR-155-5p, miR-152-3p, and miR-137 were analyzed. Finally, methylation of miRNA host genes was associated with PCa progression.
Results

DNA methylation analysis
Microarray-based DNA methylation analysis was performed of 9 pairs of PCa and noncancerous prostate tissue (NPT) samples. According to the microarray design, 7.1% of biological probes (16853 of 237203) were annotated as associated with miRNA host genes, representing 88.6% of all miRNA genes residing in host genes in total (1248 of 1409; Fig. 1A ). Comparing PCa to NPT samples, significant methylation differences (FC ! 1.5; P < 0.0500) were identified in 522 miRNA host genes of which 333 were hypermethylated and 283 hypomethylated, including 94 overlapping genes (Fig. 1B) . In BCR-positive as compared to BCR-negative PCa cases, methylation differences were less common (FC ! 1.2, P < 0.0500) and significantly differed according to 129 host genes, consisting of 58 hypermethylated and 74 hypomethylated genes with 3 gene overlap (Fig. 1B) . Lists of top 50 genes showing significantly different methylation levels in group comparisons are provided in Supplementary Material, Table S1 . Based on methylation levels according to tissue histology or BCR status and with regard to the number of a particular gene-associated probes showing significant methylation differences, five miRNA coding loci were selected for further DNA methylation analysis (Table 1) .
DNA methylation status of the regulatory regions of the 5 selected miRNAs was examined by means of methylationspecific PCR (MSP). Promoter-associated CpG islands of mir-155, mir-152, and mir-137 host genes were frequently hypermethylated in PCa, but not in NPT and/or benign prostatic hyperplasia (BPH) samples (all P < 0.0500; Fig. 2A ). Hypermethylation of mir-31 and mir-642a, -b promoters was rarely detected in PCa, while mir-642a, -b was the only miRNA whose hypermethylation was observed in BPH ( Fig. 2A) . Promoter methylation of mir-137 host gene was more frequent in tumors expressing TMPRSS2-ERG fusion transcript (P ¼ 0.0010; Fig. 2B ). Mir-152 and mir-137 methylation frequency significantly increased according to Gleason grade groups assigned according to recommendations of International Society of Urological Pathology (ISUP) (14) , while a trend was observed for mir-155 (P ¼ 0.0252, P ¼ 0.0355, and P > 0.0500, respectively; Fig. 2C ). Associations with other parameters are provided in Supplementary Material, Table S2 .
For the quantitative analysis of the methylation at the miRNA host gene promoter regions, the prostate adenocarcinoma (PRAD) dataset of TCGA, restricted to the data from nondegraded samples, was used (333 tumors in total). Level 3 TCGA data were obtained using cBioPortal for Cancer Genomics (http://www.cbioportal.org; date last accessed September 25, 2016) . Similarly to our data, mir-155, mir-152, mir-137, and mir-31 showed significantly higher methylation levels in tumors than in normal prostate tissues (all P < 0.0001; Supplementary Material, Fig. S1 ). Besides, in this dataset, the difference of methylation levels was also significant for mir-642a, -b host gene (P ¼ 0.0013).
MiRNA expression and association with DNA methylation
To assess whether the host gene promoter methylation status was associated with the deregulation of the analyzed miRNAs, the expression levels of the predominant mature miRNA sequences -miR-155-5p, miR-152-3p, miR-137, and miR-31-5p -were reanalyzed in a set of 41 PCa and 12 NPT cases from our previous study (15) . Highly significant downregulation of miR-155-5p, miR-152-3p, and miR-31-5p was detected in PCa as compared to NPT samples, however, no difference in expression levels of miR-137 was observed (Fig. 3) . Matched miRNA expression and DNA methylation data were available for a subset of 30 PCa and 7 NPT cases. Decreased miR-155-5p expression significantly correlated with the methylated promoter status (P ¼ 0.0375), however, no associations between miRNA expression and host gene promoter methylation was observed for other miRNAs (all P > 0.0500; data not shown).
For the validation in a larger set of samples, expression of the selected miRNAs was also investigated in the PRAD cohort of TCGA. In this dataset, downregulation of mir-155 and mir-152 significantly correlated with higher promoter methylation levels of their host genes (R P ¼ À0.23, P < 0.0001 and R P ¼ À0.25, P < 0.0001, respectively; Supplementary Material, Fig. S1 ). Moreover, promoter methylation was associated with the decreased expression of mir-155 and mir-152 host gene mRNAs (R P ¼ À0.32, P < 0.0001 and R P ¼ À0.57, P < 0.0001, respectively). Expression analysis also indicated that these two miRNAs were co-expressed with their host gene mRNAs (R P ¼ 0.74, P < 0.0001 and R P ¼ 0.32, P < 0.0001, respectively). Expression levels of mir-137 and mir-31 did not correlate with promoter methylation (both P > 0.0500; Supplementary Material, Fig. S1 ), while expression data on host genes of these miRNAs was not obtainable for more thorough analysis.
Analysis of miRNA targets
MiRNAs with the most frequent methylation of the host gene promoters in PCa -miR-155-5p, miR-152-3p, and miR-137 -were selected for their target gene analysis. The putative transcriptional targets of these miRNAs were obtained querying six online databases utilizing different methods of target prediction (Supplementary Material, Table S3 ). Large numbers of obtained predicted targets were screened for genes associated with epigenetic modulation as defined in EpiFactors database (http://epi factors.autosome.ru; date last accessed September 27, 2016) (16) . Overlapping epigenetic regulator genes were chosen for the analysis. DNA (cytosine-5-)-methyltransferase 1 (DNMT1) was selected as a target of miR-155-5p and miR-152-3p, while lysine demethylases 1A (KDM1A/LSD1) and 5B (KDM5B/JARID1B) -as targets of miR-155-5p and miR-137 ( Fig. 4A and B; Supplementary Material, Table S3 ).
In our cohort, expression levels of DNMT1 and KDM5B were higher in tumors and NPTs of PCa cases as compared to BPH and, thus, distinguishing PCa and BPH patients ( Fig. 4C-E ). Only expression of KDM5B was higher in PCa than in NPT cases, while 
GIPR/PGQTL2 protein-coding intron** 2 3 miR-642b-5p, -3p MIR642B 19q13.32 (-) PCa, prostate cancer; NPT, noncancerous prostate tissue, BCRþ/-, biochemical disease recurrence status (positive/negative); ncRNA, noncoding RNA. *Nomenclature of miRNAs and genes is given according to miRBase release 21 (http://www.mirbase.org; date last accessed November 15, 2016) and GeneCardsV R databases (http://www.genecards.org; date last accessed November 15, 2016). **5'-UTR/exon of predicted transcripts. no significant differences of KDM1A expression levels were observed among the histological groups. Expression of the selected target genes was further linked to the promoter methylation status of the corresponding miRNA host genes. KDM5B was expressed at higher levels in samples with methylated mir-155 or mir-137 host gene promoters (P < 0.0001 and P ¼ 0.0001, respectively), whereas increased expression of KDM1A and DNMT1 was significantly associated with mir-155 and mir-152 host gene methylation, respectively (P ¼ 0.0302 and P ¼ 0.0093; Fig. 4F-H) . Expression of KDM1A and KDM5B correlated inversely with preoperative PSA level (R S ¼ À0.29, P ¼ 0.0096 and R S ¼ À0.26, P ¼ 0.0184, respectively; Fig. 4I and J) . Moreover, the two genes were upregulated in PCa cases expressing TMPRSS2-ERG fusion transcript (P ¼ 0.0048 and P ¼ 0.0011, respectively; Fig.  4K ). No associations between DNMT1, KDM1A, or KDM5B and other variables were observed (data not shown).
In TCGA cohort, significant correlations were validated between KDM5B expression and mir-155 or mir-137 host gene promoter methylation (R P ¼ 0.18, P ¼ 0.0007; and R P ¼ 0.32, P < 0.0001, respectively) and between KDM1A expression and mir-155 methylation (R P ¼ 0.28, P < 0.0001; Supplementary Material, Fig. S2 ). Conversely to our data, mir-137 promoter methylation level correlated with increased KDM1A expression (R P ¼ 0.40, P < 0.0001), while higher methylation levels of mir-155 were linked to increased DNMT1 expression (R P ¼ 0.16, P ¼ 0.0032). The upregulation of DNMT1 in association with methylated mir-152 promoter was also supported by the data from TCGA cohort (R P ¼ 0.12, P ¼ 0.0236; Supplementary Material, Fig. S2 ).
MiRNA host gene methylation and BCR-free survival
Having shown the impact of miRNA host gene methylation on corresponding miRNA and target mRNA expression, we aimed to determine the prognostic value of these observations. Methylation of mir-152 and mir-31 host gene promoters was significantly more common in BCR-positive than BCR-negative cases (P ¼ 0.0213 and P ¼ 0.0191, respectively) and the same tendency was observed for mir-155 (P > 0.0500; Fig. 2D ). KaplanMeier analysis revealed that methylation of mir-155, mir-152, or mir-31 promoter has significant negative impact on BCR-free survival, whereas no association was observed for mir-137 (P ¼ 0.0371, P ¼ 0.0193, P ¼ 0.0102, and P > 0.0500, respectively; Significant P values are marked in bold. Fig. 5A-D) . Expression levels of miRNA target genes DNMT1, KDM1A, and KDM5B were not associated with BCR status (all P > 0.0500; data not shown).
Univariate Cox proportional hazard analysis confirmed the association of promoter methylation status of mir-155, mir-152, and mir-31 host genes with BCR-free survival (models 'P ¼ 0.0447, P ¼ 0.0236 and P ¼ 0.0168, respectively; Supplementary Material, Table S4 ). Combinations of methylation status of various miRNA host genes also showed prognostic value in multivariate models, among which a combination of mir-152 and mir-31 was the most significant (models' P ¼ 0.0130). Moreover, multivariate analysis revealed that promoter methylation of mir-155 host gene alone or together with mir-152 was prognostic for BCR-free survival in combination with TMPRSS2-ERG fusion-negative status (models' P ¼ 0.0333 and P ¼ 0.0151, respectively; Supplementary Material, Table S4 ). Among clinicopathologic parameters, various combinations were prognostic of BCR-free survival, but only pT and ISUP grade group showed independent prognostic value (models' P ¼ 0.0001 and P < 0.0001, respectively; Supplementary Material, Table S4 ). Forward entering of covariates revealed that methylation status of mir-152 or mir-31 host genes together with pT even better predicted BCR-free survival than the clinicopathologic variable alone (both models' P < 0.0001). Moreover, methylation of mir-31 also had the same effect in combination with ISUP grade group (models' P < 0.0001). Other combinations of miRNAs with clinicopathologic variables were also rather promising (Supplementary Material, Table S4 ).
For TCGA data, disease-free survival, in addition to BCR-free survival, was utilized as an endpoint for the evaluation of prognostic potential of the selected biomarkers. PCa cases with prior cancer diagnosis and/or prior neoadjuvant therapy, having Gleason score 10, and metastatic cases were eliminated from the survival analysis, leaving 306 of 333 cases, in order to better match the Lithuanian cohort. In TCGA cohort, higher methylation levels of mir-137 and mir-31 host genes were associated with disease-free (P ¼ 0.0110 and P ¼ 0.0130, respectively), but not with BCR-free survival (both P > 0.0500; data not shown), and these associations were supported by univariate Cox models (models' P ¼ 0.0122 and P ¼ 0.0188, respectively). In multivariate analysis, forward entering of covariates showed that methylation levels of mir-137 or mir-31 host genes increased the prognostic value of pT (models' P ¼ 0.0006 and P ¼ 0.0007, respectively; Supplementary Material, Table S4 ).
Although expression of the analyzed miRNA targets was not prognostic for BCR status in our cohort, higher expression levels of KDM5B were characteristic to shorter BCR-free survival in TCGA cohort (P ¼ 0.0093), while increased DNMT1 expression significantly predicted time to disease relapse (P ¼ 0.0033; Supplementary Material, Table S4 ). Various multivariate models of target genes alone or in combinations with promoter methylation of the respective regulatory miRNAs were also prognostic for BCR-free and/or disease-free survival. However, none of the multivariate models surpassed the significance of the individual variables (data not shown).
Discussion
For the last decade, the role of miRNAs in the maintenance of cellular homeostasis and cancer development has been widely accepted. A rapidly growing amount of miRNA expression profiling studies has revealed a wide range of alterations in miRNA expression. Although the mechanisms responsible for deregulated miRNA expression are still not fully understood, miRNA silencing linked to aberrant DNA methylation at promoter regions appears to be of major importance in disrupting miRNA profile in various cancer types including prostate cancer (17) (18) (19) (20) .
The present study let us identify PCa-specific promoter methylation of mir-155 host gene accompanied by significant downregulation of the mature miRNA. To date, DNA methylation, as a mechanism involved in mir-155 regulation, has been described in a few studies analyzing breast cancer (21), multiple myeloma (22) , and gastric cancer cell lines (23) . Therefore, this is the first study to report mir-155 host gene methylation in PCa associated with miRNA silencing. Due to interactions with its various targets, miR-155-5p is considered as a multifunctional miRNA as ambiguous data have been obtained from different types of cancer (24) (25) (26) . This discrepancy might be partly explained by differences in cohort composition and/or model systems used. MiR-152 is another frequently studied miRNA, however, only a few reports investigating its regulation by CpG island methylation exist (27, 28) . In addition to aberrant methylation in PCa samples as compared to NPT or BPH, our results showed that the promoter of mir-152 host gene was also more frequently methylated in higher ISUP grade tumors and was associated with higher PSA level, demonstrating potential clinical significance. Supporting our data, miR-152 inactivation was found associated with promoter methylation in PCa cell lines by other authors (18) . Interestingly, decrease in miR-152 expression was more common in PCa tissues of African American patients as compared to Caucasians (18) .
Recently, extensive methylation of mir-137 locus has emerged as a significant phenomenon in different types of tumors (21, 29, 30) including pre-clinical PCa cell models of localized and castrate resistant cancer (19) . In our study, more frequent promoter methylation of mir-137 host gene was detected in PCa versus NPT and BPH samples. Similarly to the analysis of a clinical dataset in a recent study (19) , this miRNA was more commonly methylated in tumors of higher ISUP grade in the present study. However, promoter methylation-associated miR-137 silencing was confirmed only in TCGA data, most likely due to a limited number of cases in our cohort.
Survival analysis revealed that promoter methylation status of mir-155, mir-152, and mir-31 host genes was significant as independent predictor of BCR-free survival in univariate and various multivariate models and even enhanced the prognostic potential of clinicopathologic variables. Methylation status of mir-155 as a covariate contributed to various multivariate models. In particular, mir-155 alone or together with mir-152 significantly predicted time to BCR in PCa cases with negative TMPRSS2-ERG fusion status. Despite the low methylation frequency in PCa, mir-31 augmented the prognostic value of tumor stage and ISUP grade group and also significantly predicted disease-free survival in TCGA data analysis. To date, the prognostic potential of these miRNAs has been mostly evaluated at the miRNA expression level (31, 32) , whereas studies analyzing the effect of epigenetic repression on PCa patient's survival are lacking (10) . Consistent with our data, loss of miR-155, miR-152, miR-137, and miR-31 and other tumorsuppressive miRNAs has been associated with BCR or disease progression in PCa, but the main set of these studies has been performed on treatment-resistant cell lines and rarely in large groups of PCa cases (15, 18, (31) (32) (33) .
Recent evidences suggest the idea that deregulated miRNAs may lead to aberrant DNA methylation and histone modification profile observed in cancer (reviewed in 6). Therefore, after querying 6 miRNA target databases and recent publications as well, we focused on epigenetic regulatory genes, previously shown to play a role in cancer epigenome remodeling. DNA methyltransferase 1 (DNMT1), mainly responsible for maintaining methylation patterns following DNA replication, has been validated as a target of miR-152-3p in endometrial tumors and PCa cell lines (9, 18, 34) , whereas targeting by miR-155-5p is predicted by bioinformatic tools and is weakly substantiated (35) . Our results indicated higher DNTM1 expression levels in cancerous and NPT samples as compared to BPH. In support with previous studies, upregulation of DNMT1 was determined in PCa cases with methylated mir-152 promoter, but no such correlation was observed for mir-155. However, associations of DNMT1 expression with promoter methylation levels of the host genes were observed for the both miRNAs analyzing TCGA data, which might be produced due to different sample sizes and other characteristics. Besides epigenetic regulation of DNMT1, a direct binding of miR-155-5p to the catalytic region of DNMT1 enzyme was recently shown (12) suggesting further need for functional studies of miR-155-5p in cancer cells.
Lysine-specific histone demethylases (KDMs) play important roles in PCa progression and particularly in transition from the androgen-dependent to androgen-independent state. KDM1A is the first identified and the most deeply studied lysine demethylase. It specifically demethylates H3K4me1/2 and, therefore, favors gene silencing. However, when recruited by androgen receptor (AR) KDM1A mainly acts as a coactivator in PCa by removing H3K9me1/2 repressive marks and leading to the activation of AR signaling (36, 37) . In the present study, no expression differences of KDM1A were observed between PCa and NPT samples or in association with BCR status in Lithuanian cohort. However, higher KDM1A levels alone or in combination with other molecular markers had prognostic significance predicting BCR-free and/or disease-free survival in TCGA data. High KDM1A expression in primary PCa has been also shown to predict higher risk of relapse after prostatectomy in other studies (37) . A recent study (38) has provided mechanistic insight into the formation of the TMPRSS2-ERG fusion and showed that KDM1A is critically important for this gene rearrangement, as well as for the expression of the fusion transcript (38) . Supporting the fact, we found significantly higher KDM1A expression in PCa cases with TMPRSS2-ERG fusion. MiR-137 has been previously shown to target KDM1A in colorectal cancer cells (39) , while miR-155-5p interaction with this lysine-specific demethylase is only predicted. In support to this notion, we determined higher KMD1A expression in cases with methylated mir-155 host gene promoter status both in Lithuanian and TCGA datasets, however, similar association with mir-137 methylation was observed only in TCGA cohort.
Overexpression of another lysine-specific demethylase (H3K4me2/3), KDM5B, has been observed in PCa (40) . Consistently, we found significant differences of KDM5B levels in prostate tissues, with the highest expression observed in PCa. Similarly to KDM1A, the expression of KDM5B was also significantly higher in TMPRSS2-ERG positive PCa cases. KDM5B has been recently identified as a target of miR-137 in PCa cell lines (19) , while the same role of miR-155-5p has been only predicted by computational methods. To the best of our knowledge, our study for the first time associated the upregulated KDM5B expression with methylated status of mir-137 and mir-155 host gene promoters. This was validated in TCGA cohort further signifying the importance of these two miRNAs in PCa development. However, further experimental evidence supporting the direct regulation of KDM5B, as well as KDM1A, expression by miR-155-5p is needed. Previous studies have confirmed that KDM5B, like KDM1A, also interacts with AR and acts as an oncogene (40) , although the mechanism is not yet fully understood. Taken together, this data suggests that KDMs might play a far more complex role in prostate carcinogenesis that transcends our current knowledge.
In conclusion, our study has shown aberrant promoter methylation of mir-155, mir-152, mir-137, and mir-31 host genes as promising diagnostic and/or prognostic biomarkers of PCa. Our observations suggest that methylation status of particular miRNA host genes as independent variables or in combinations can predict BCR-free survival and even increase the prognostic value of clinicopathologic variables. Aberrantly methylated miRNA host genes, as well as epigenetic factors regulated by these miRNAs, might be attractive targets for epigenetic therapeutics.
Materials and Methods
Patients and samples
Prostate tissue samples were collected from 129 PCa patients and 17 BPH patients who underwent RP or open prostatectomy, respectively, at the Urology Center of Vilnius University Hospital Santariskiu Clinics from 2008 to 2014. Tissues were sampled and tumor cellularity was evaluated by an expert pathologist as reported previously (41) . Thirty five NPT samples (0% of tumor cells mostly) from PCa patients were also available for the investigation. Approval from the Lithuanian Bioethics Committee was obtained before initiating the study, and later for the microarray analysis, and all patients gave informed consent for participation.
Gleason score was obtained according to ISUP 2005 guidelines and ISUP grade groups were assigned according to ISUP 2014 recommendations (14, 42) . In agreement with EAU-ESTRO-SIOG Guidelines on Prostate Cancer 2016, BCR was defined by two consecutive increases !0.2 ng/ml in serum PSA level after RP (43) . Follow-up data were available for 91.5% (118/129) of patients with a mean follow-up time of 3.4 years. The identification of TMPRSS2-ERG fusion transcript status was reported previously (41, 44) . Clinicopathologic and molecular characteristics of the study subsets are provided in Supplementary Material, Table S5 . None of the patients had preoperatively received radiotherapy, chemotherapy, or hormone therapy. The workflow of the study is provided in Supplementary Material, Figure S3 .
DNA methylation microarrays
Global DNA methylation profiling of 9 cancerous and NPT tissue pairs from PCa patients with thorough medical histories was performed using two-color Human DNA Methylation 1 Â 244K Microarrays (GEO accession identifier GSE89243) according to the manufacturer's protocol (Agilent Technologies, Santa Clara, CA, USA) as described previously (45) and utilized for the analysis of miRNA host gene-associated loci. Probe annotations, based on microarray design identifier, were uploaded from SureDesign platform (https://earray.chem.agilent.com/surede sign; date last accessed September 25, 2016) and updated using UCSC Genome Browser (https://genome.ucsc.edu; date last accessed October 4, 2016) according to the human genome assembly version GRCh38. MiRBase release 21 was used for obtaining miRNA annotations (http://www.mirbase.org; date last accessed November 15, 2016) . Randomly selected annotations ($1%) were checked manually. Saturated, non-uniform, and outlier probe signals were treated as compromised and probes measured in <30% of tumor samples were filtered out as undetected. For the comparison of two groups, fold change (FC) value was estimated and paired (where applicable) or unpaired t-test was applied. Calculations were performed with GeneSpring GX v13.1.1 software (Agilent Technologies). Figure S4 .
DNA extraction and bisulfite conversion
MiRNA expression analysis
Quantitative miRNA expression data were extracted from our previous study based on the samples from the same PCa cohort (15) . For the re-analysis, raw Cq values of miRNA expression from the TaqManV R Low Density Array-based screening using Human MicroRNA A þ B Cards Set v3.0 (Applied Biosystems  TM ) were obtained for a set of 41 PCa and 12 NPT samples (Supplementary Material, Table S5 ). Data preprocessing was performed using GenEx v6.0.1 software (MultiD Analyses AB, Gö teburg, Sweden). Considering the epigenetic silencing of miRNA expression, missing Cq values (due to the amplification below the threshold or none at all) were equated to 40. Expression levels of miR-155-5p, miR-152-3p, miR-137, and miR-31-5p were normalized to RNU44 and RNU48 as endogenous controls, as suggested by the manufacturer, and converted to relative values in a linear scale. Expression of miR-155-3p was undetected in all of the selected samples and, therefore, was omitted from the analysis.
RNA extraction and gene expression analysis by RT-qPCR
Total RNA (including miRNA fraction) was extracted from $30 mg of homogenized tissue using mirVana TM miRNA Isolation Kit (AmbionV R , Thermo Fisher Scientific, Foster City, CA, USA) as described previously (15, 44) . Quantity and quality of the extracted RNA were evaluated using 2100 Bioanalyzer (Agilent Technologies) and only samples having high purity parameters and RNA integrity number (RIN) >7 were submitted for the analysis (Table S5) . For cDNA synthesis, 250 ng of RNA was reverse transcribed (RT) using High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor according to the manufacturer's protocol (Applied Biosystems   TM ). Expression levels of 3 miRNA target genes DNMT1, KDM1A, KDM5B, and endogenous control HPRT1 were evaluated by means of quantitative PCR (RT-qPCR) using TaqManV R Gene Expression Assays (Hs00945900_g1, Hs01002741_m1, Hs009 81910_m1, and Hs02800695_m1, respectively; Applied Biosystems TM ). The reaction mix (20 ml) consisted of 10 mL of TaqManV R Universal Master Mix II no UNG (Applied Biosystems TM ), 0.6 mL of TaqManV R assay, and 2 mL of RT reaction product (equivalent to 25 ng of total RNA). RT-qPCR was performed on the Mx3005P qPCR System (Agilent Technologies) in triplicates per gene. Thermal cycling conditions consisted of 95 C for 10 min, followed by 40 cycles of 95 C for 15 s and 60 C for 1 min.
Multiple non-template controls were included in each RT-qPCR run. Data preprocessing was performed with GenEx v.6.0.1 software (MultiD Analyses, Gö teborg, Sweden).
Statistical analysis
Statistical analysis was performed using STATISTICA TM v8.0 (StatSoft, Tulsa, OK, USA) and GraphPad Prism software (GraphPad Software, La Jolla, CA, USA). The 2-sided Fisher's exact test or Kruskal-Wallis test was used for comparison of categorical variables. Continuous variables were compared by Student's t-test or by Mann-Whitney U test for normally or nonnormally distributed variables, respectively. Pearson (R P ) and/or Spearman's (R S ) rank correlation coefficients were calculated to test the associations between two variables. TCGA dataset of PRAD was used for comparison. For the analysis of RT-qPCR and TCGA data, appropriate parametric tests were applied. For BCRfree survival analysis, Kaplan-Meier curves were compared with log-rank test and Cox proportional hazards modeling was performed. Hazard ratios with 95% confidence intervals were estimated. To avoid overfitting of models, only up to 4 covariates were included in multivariate analysis. Differences and associations were considered statistically significant at P < 0.0500.
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